 Home > Active Ingredient News > Drugs Articles > From gene editing to artificial intelligence, these 15 companies represent the future trend of medical technology

From gene editing to artificial intelligence, these 15 companies represent the future trend of medical technology

 Last Update: 2021-03-22
 Source: Internet
 Author: User

Tags

take

key resin company

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

us" style='margin:0px;padding:0px;max-width:100%;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.

Today, FierceMedTech announced the ninth annual medical technology "Meng" company (Fierce 15) list.
Every year, FierceMedTech selects the annual Fierce 15 list from hundreds of private companies around the world based on many factors such as corporate technical strength, partners, venture capitalists, and market position.

The outbreak of the new crown epidemic has also stimulated innovation in the field of medical technology to combat the epidemic.

Mr.

Today, FierceMedTech announced the ninth annual medical technology "Meng" company (Fierce 15) list.

Every year, FierceMedTech selects the annual Fierce 15 list from hundreds of private companies around the world based on many factors such as corporate technical strength, partners, venture capitalists, and market position.

The outbreak of the new crown epidemic has also stimulated innovation in the field of medical technology to combat the epidemic.

Among the cutting-edge companies on the list today, some use CRISPR technology to develop simple and accurate detection methods for the new crown virus, and some use the promotion of telemedicine to solve the problem of treating patients.
The difficulties encountered are also the use of artificial intelligence to improve disease treatment and drug development methods.

Mr.

Conor Hale, deputy editor of FierceMedTech, believes that these technological innovations may not only help fight the new crown pandemic, but also have a profound impact on human health after the pandemic is over.
Let’s take a look at how these innovative companies’ new technologies benefit patients and medical staff.

These technological innovations may not only help fight the new crown pandemic, but after the pandemic is over, they will still have a profound impact on human health.

Mammoth Biosciences: Using CRISPR technology to find clues about pathogens

Mammoth Biosciences: Use CRISPR technology to find clues about pathogens Mammoth Biosciences: Use CRISPR technology to find clues about pathogens

544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style='margin:0px;padding:0px;max-width:100%;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
95;box-sizing:border-box ;overflow-wrap:break-word ;'>

Mammoth Biosciences was co-founded by Dr.

Jennifer Doudna, a CRISPR pioneer and 2020 weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649998957&idx=1&sn=e331b94543e3a165628fa383be332d9b&scene=21#wechat_redirect" target="_blank" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Nobel Prize winner weixin.
qq.

Last year, Mammoth's new coronavirus detection based on CRISPR technology received an emergency use authorization granted by the US FDA.
The company has also developed a test based on mobile phone cameras that can detect the new coronavirus weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649999088&idx=1&sn=11e652eba0998af1f08e9937f8e22070&scene=21#wechat_redirect" target="_blank" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">without using PCR .

In addition to detecting the new coronavirus, Mammoth's goal is to develop molecular tests that can detect pathogens that cause multiple diseases through a single test, and to develop a new CRISPR gene editing system.

C2N Diagnostics: A simple blood test found amyloid deposits in patients with Alzheimer's disease

Mammoth Biosciences was co-founded by Dr.
Jennifer Doudna, a CRISPR pioneer and 2020 weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649998957&idx=1&sn=e331b94543e3a165628fa383be332d9b&scene=21#wechat_redirect" target="_blank" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">Nobel Prize winner weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649998957&idx=1&sn=e331b94543e3a165628fa383be332d9b&scene=21#wechat_redirect" target="_blank" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">in chemistry .
It aims to use CRISPR gene editing technology to develop molecular diagnostic tests for the detection of viral and bacterial genome sequences.
Its potential lies in keeping the detection accuracy comparable to that of traditional PCR, while requiring less hardware and laboratory resources to promote the application of molecular diagnostics.

weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649998957&idx=1&sn=e331b94543e3a165628fa383be332d9b&scene=21#wechat_redirect" target="_blank" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">The Nobel Prize in Chemistry maintains the same detection accuracy as traditional PCR, but requires less hardware and laboratory resources to promote the application of molecular diagnostics.

The company has also developed a mobile phone-based camera, weixin.
qq.
com/s?__biz=MzAwMDA5NTIxNQ==&mid=2649999088&idx=1&sn=11e652eba0998af1f08e9937f8e22070&scene=21#wechat_redirect" target="_blank" data-linktype="2" style="margin:0px;padding:0px;color:#576B95;text-decoration-line:none;-webkit-tap-highlight-color:rgba(0, 0, 0, 0);cursor:pointer;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">without the use of PCR without the use of PCR without the use of PCR can detect the new virus test crown.

C2N Diagnostics: A simple blood test found amyloid deposits in patients with Alzheimer's disease

C2N Diagnostics：，C2N Diagnostics：，

us" style='margin:10px 0px;padding:0px;max-width:100%;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>us" style='margin:0px;padding:0px;max-width:100%;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
95;box-sizing:border-box ;overflow-wrap:break-word ;'>

（AD），，，。，AD，（Biogen）aducanumabFDA。

，，PET，，。、AD，。

C2N Diagnostics，APOE，APOEAD。，。686，86%PET。

Alydia Health：

（AD），，，。，AD，（Biogen）aducanumabFDA。

，，PET，，。、AD，。

C2N Diagnostics，APOE，APOEAD。，。686，86%PET。

C2N Diagnostics，APOE686，86%PET。

Alydia Health：

Alydia Health：Alydia Health：

In the past 30 years, the maternal mortality rate in the United States has gradually increased.
Many birth-related deaths stem from postpartum hemorrhage, because the uterus of the parturient does not have the strength to continue to contract after birth, which causes the damaged blood vessels connected to the placenta to bleed continuously, which brings danger to the parturient.

Alydia Health's Jada system uses an innovative strategy that uses a slight vacuum inside the uterus to tighten the uterine walls and maintain their natural shape, thereby compressing blood vessels to achieve the goal of hemostasis.
This strategy avoids the potential side effects that may be caused by currently used hemostatic drugs or medical devices.

A published clinical study shows that this system can completely control postpartum hemorrhage within 3 minutes, with a success rate of 94%.
In September last year, the FDA approved this system for marketing.

Avail Medsystems: Using virtual technology to "move" external experts into the operating room

This system can completely control postpartum hemorrhage within 3 minutes, with a success rate of 94%.
In September last year, the FDA approved this system for marketing.

Avail Medsystems: Using virtual technology to "move" external experts into the operating room

Avail Medsystems: "Move" external experts into the operating room through virtual technology Avail Medsystems: "Move" external experts into the operating room through virtual technology

When performing an operation, there are not only patients and doctors in the operating room.
When certain medical devices are used, representatives of manufacturers who produce medical devices also need to be present.
For medical devices under research and newly marketed, this is an important procedure for evaluating their safety and effectiveness.
However, a variety of reasons may prevent company representatives from being present.
The new crown pandemic has undoubtedly made it more difficult to meet this requirement, and may even delay the operation of patients.

Avail’s solution is to use virtual technology to “connect” doctors performing operations with external experts.
The system it has developed includes multiple high-definition cameras that can be remotely controlled, allowing external experts to see and hear the entire procedure, and can provide doctors with advice in real time.

The company completed a $100 million Series B financing in October last year.
It is expected that Avail's remote system will be deployed in hundreds of hospitals before the end of this year.

Babson Diagnostics: Make blood tests easier and more popular

Avail's solution is to use virtual technology to "connect" doctors performing operations with external experts.

The company completed a $100 million Series B financing in October last year.
It is expected that Avail's remote system will be deployed in hundreds of hospitals before the end of this year.

Babson Diagnostics: Make blood tests easier and more popular

Babson Diagnostics: Make blood tests easier and more popular Babson Diagnostics: Make blood tests easier and more popular

The COVID-19 pandemic has made people more deeply aware of the importance of simple and accurate testing.
The current routine blood test requires blood to be drawn from a vein, while the blood test technology developed by Babson Diagnostics is designed to draw blood from a patient’s fingertips.
The amount of blood required is only one-tenth of that of a conventional blood test, and it remains the same as a conventional test.
The quality of testing.

Babson's automated blood processing system can reduce the waste in blood collection and processing by 93% , and it can be used by simply trained medical staff in ordinary pharmacies.
The company's goal is to make blood tests easier and more popular, so that people can more easily obtain their own health information through blood tests, and help them make decisions to improve their health.

Canary Medical: Building an intelligent artificial knee

By drawing blood from a patient’s fingertips, the amount of blood required is only one-tenth of that of a routine blood test, and the quality of the test is the same as that of a routine test.

Reduce waste in blood collection and processing by 93%

Canary Medical: Building an intelligent artificial knee

Canary Medical: Building an Intelligent Artificial Knee Canary Medical: Building an Intelligent Artificial Knee

Canary Medical（Internet of Things），。，。，，（），。

，、XCT，，Canary，。FDA，。

Caption Health：

Canary Medical（Internet of Things），。，。，，（），。

（Internet of Things），。

，、XCT，，Canary，。FDA，。

Caption Health：

Caption Health：Caption Health：

，，，。

Caption Health，。，，。

，，。FDA。

Cue Health：

，，，。

Caption Health，。，，。

，，。FDA。

Cue Health：

Cue Health：Cue Health：

us" style='margin:10px 0px;padding:0px;max-width:100%;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;'>797px;height:auto;">797px;height:auto;">us" style='margin:0px;padding:0px;max-width:100%;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:15px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
95;box-sizing:border-box ;overflow-wrap:break-word ;'>

Cue Health focuses on the development of a molecular diagnostic platform that is fast, compact and highly portable.
The company’s portable molecular diagnostic system has been authorized by the US FDA for emergency use .
It can be used in conjunction with a disposable test kit to perform PCR-based molecular testing on nasal swab samples within 20 minutes and give it via smartphone New coronavirus test results.

This test has recently received an emergency use authorization from the FDA, allowing it to be used at home to test individuals over two years of age without a doctor's prescription.
The results of the study showed that compared with the highly sensitive laboratory-based PCR test authorized by the FDA, this test reached 97.
4% consistency when it found positive patients and 99.
1% when it found negative patients.

CVRx: Treating heart failure by "deceiving" the brain

Within 20 minutes, PCR-based molecular testing can be performed on nasal swab samples, and the new coronavirus test results can be given through a smartphone.

It does not require a doctor's prescription and can be used at home to test individuals over two years of age.
This test achieves a 97.
4% agreement when it finds a positive patient and a 99.
1% agreement when it finds a negative patient.

CVRx: Treating heart failure by "deceiving" the brain

CVRx: Treating heart failure by "deceiving" the brain CVRx: Treating heart failure by "deceiving" the brain

Generally, drugs and medical devices used to treat heart failure relieve the symptoms of heart failure in two ways.
Drugs are designed to reduce the burden on the heart so that it can more easily pump blood to other parts of the body, and medical devices use electrical stimulation to control the rhythm of the heart's beating.

CVRx uses a completely different strategy.
The company believes that one of the reasons for the symptoms of heart failure is the imbalance of the sympathetic and parasympathetic nerve signals that control the beating of the heart, causing the heart to remain in a state of tension.
The Barostim system developed by the company is implanted under the clavicle.
Its electrodes can stimulate pressure-sensing receptors in arteries and blood vessels, making the brain "feel" insufficient oxygen intake.
The brain will therefore reduce sympathetic nerve activity and increase parasympathetic nerve activity, leading to vasodilation.

The FDA has approved this system in August 2019 for the treatment of patients with advanced heart failure.

Ellume: Design a fast and accurate digital diagnostic test

Its electrodes can stimulate pressure-sensing receptors in arteries and blood vessels, making the brain "feel" insufficient oxygen intake.
The brain will therefore reduce sympathetic nerve activity and increase parasympathetic nerve activity, leading to vasodilation.

The FDA has approved this system in August 2019 for the treatment of patients with advanced heart failure.

Ellume: Design a fast and accurate digital diagnostic test

Ellume: Design a fast and accurate digital diagnostic test Ellume: Design a fast and accurate digital diagnostic test

The fluorescence immunoassay platform developed by Ellume uses fluorescent nanoparticles based on quantum dots.
During the COVID-19 epidemic, the new coronavirus antigen test developed by the company has been authorized by the FDA for emergency use and can be used to detect the new coronavirus without a doctor's prescription.
Compared with standard nucleic acid tests, this antigen test achieves 96% consistency in the detection of positive results when testing symptomatic COVID-19 patients, and 100% consistency in the confirmation of negative results .

This new coronavirus test not only has a sample measurement system that can notify users when the sample is insufficient, but also combines with the smartphone APP to provide users with detailed instructions for testing, and the test data can be automatically transmitted to public health agencies, thereby Provide information for tracking diseases.

In addition to testing for the new coronavirus, the company is also working with GlaxoSmithKline's (GSK) Consumer Health Department to develop home tests for influenza.

Foldax: Building a new generation of heart valves

The fluorescence immunoassay platform developed by Ellume uses quantum dot-based fluorescent nanoparticles.
96% 100%

In addition to testing for the new coronavirus, the company is also working with GlaxoSmithKline's (GSK) Consumer Health Department to develop home tests for influenza.

Foldax: Building a new generation of heart valves

Foldax: Building a new generation of heart valves Foldax: Building a new generation of heart valves

Heart valves currently used for transplant surgery have different limitations.
Heart valves constructed from animal tissues are usually manufactured with complex manufacturing processes and limited durability.
They may also have the risk of spreading diseases.
Although mechanical heart valves have good durability, patients need to be treated with blood thinners throughout their lives, which will affect their quality of life.

The heart valve manufactured by Foldax uses an innovative biopolymer , which can withstand the tension generated by the human heart, while being biocompatible and stable, and can benefit patients for life without anticoagulant drugs.
.

，。Frank Maguire，3，10，10，。

，。

Hyperfine Research：

，，，。，，。

Foldax（biopolymer），，，。

Foldax（biopolymer）

，。Frank Maguire，3，10，10，。

。

，。

Hyperfine Research：

Hyperfine Research：Hyperfine Research：

（MRI），。Hyperfine ResearchMRIMRI。，。，，MRI。

The FDA approved the MRI system for the market last year, and Hyperfine Research has also developed an artificial intelligence software system that can identify signs of brain damage through the analysis of MRI images and warn doctors.

IsoPlexis: Proteomics research at the single-cell level

Speaking of MRI systems, we might think of large instruments in hospitals that weigh several kilos.
The portable MRI system designed by Hyperfine Research is the first MRI system light enough to fit in an elevator.
It can be pushed to the patient's bedside by medical staff to provide head and brain scans.
This may be particularly important for patients in emergency wards, who do not need to be transferred to other parts of the hospital for MRI scans.

The first MRI system light enough to fit in an elevator.
It can be pushed to the patient's bedside by medical staff to provide head and brain scans.

IsoPlexis: Proteomics research at the single-cell level

IsoPlexis: Proteomics research at the single cell level IsoPlexis: Proteomics research at the single cell level

The single-cell proteomics research system developed by IsoPlexis can tag hundreds of cells with unique antibody tags, and then track and analyze the various proteins secreted by them at the single-cell level.
This single-cell-level proteomic study may help discover the cell types that play a major role in specific diseases.
The company's IsoSpark is a benchtop single cell analyzer that can be used in large or small laboratories.

BenevolentAI: Using artificial intelligence and machine learning to reconstruct the model of drug discovery

BenevolentAI: Using artificial intelligence and machine learning to reconstruct the model of drug discovery BenevolentAI: Using artificial intelligence and machine learning to reconstruct the model of drug discovery

The outbreak of the COVID-19 pandemic once paralyzed many clinical studies and severely affected the progress of research and development.
However, it also became an opportunity for BenevolentAI to test its AI-based drug discovery model.

Last year, BenevolentAI’s team published a study in The Lancet that the company’s drug development model showed that Eli Lilly and Company’s rheumatoid arthritis drug Olumiant (baricitinib) can not only reduce inflammation, And it can prevent the new coronavirus from infecting lung cells by inhibiting the protein called AAK1.
This research prompted Eli Lilly to launch a phase 3 clinical trial last summer to test the effectiveness of Olumiant and Redecive in the treatment of COVID-19 patients.

Clinical trial results show that this combination can shorten the time required for patients to recover.
They have obtained emergency use authorization granted by the FDA for the treatment of specific hospitalized COVID-19 patients.

This year, the BenevolentAI team cooperated with AstraZeneca to use AI to discover a new kidney disease target for the first time.
This target discovered through AI was verified by AstraZeneca researchers in subsequent experiments and has now entered AstraZeneca’s R&D pipeline was established.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.